Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.

Artificial Intelligence (AI) has significantly transformed high throughput screening (HTS) in drug discovery, increasing efficiency, accuracy, and predictive capabilities in early drug development stages. This research highlights AI's integration into HTS processes, showcasing improved outcomes in hit identification, assay optimization, and target validation, thus accelerating and refining the search for new medications.

Iambic Therapeutics’ protein structure predictive model, NeuralPLexer2, surpasses AlphaFold2’s abilities.

Machine learning model paves the way for predicting lung cancer.

Discover the transformative role of AI and ML in improving ligand-based virtual screening outcomes, from breakthrough drug candidate identification to overcoming challenges in data quality and computational resources

AstraZeneca’s Sridevi Nagarajan discusses the importance of artificial intelligence, strategic collaboration, and the role of the metaverse in unlocking the future of digital regulatory.

AlphaFold is the protein folding solution that took computational biology by storm, but has the protein folding problem been well and truly solved?

The fastest way to find evidence, explore hidden connections, and make new predictions

Our expert panel discuss the implementation of AI and ML tools for drug design: predictive models, computational chemistry, and AlphaFold.

The collaboration involves granting the university access to Pharos' proprietary AI platform, Chemiverse, while Pharos will collaborate with the university's drug discovery researchers and infrastructure.

Jissy Akkarapattiakal Kuriappan, Principal Investigator, Drug Discovery at Alembic Pharmaceuticals, discusses using AI to promote drug discovery, the problem with using AI as a black box, and whether AI and ML are a worthwhile investment.